Targeting a specific protein to improve prostate cancer treatment
Official title: Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapy
Funded at Duke University · NIH-11005305 · Data updated 2026-11-12
This study is exploring a new way to treat advanced prostate cancer by targeting a protein that helps cancer cells survive damage, and it's designed for patients who haven't responded to current treatments, with the hope of making those treatments work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | January 1, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $521,760 |
| NIH project number | 5R01CA279034-02 |
| Project ID | NIH-11005305 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, especially those with BRCA mutations or who have developed resistance to hormonal therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have genetic mutations related to DNA repair may not benefit from this research.
What this research studies
This research investigates a novel approach to treating prostate cancer by inhibiting a protein called Rev1, which plays a crucial role in helping cancer cells survive DNA damage. The study focuses on patients with advanced prostate cancer who have developed resistance to current therapies. By disrupting the mechanisms that allow cancer cells to tolerate DNA damage, the research aims to enhance the effectiveness of existing treatments. Patients may be monitored for their response to this new therapeutic strategy over the course of the study.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer, particularly those who have become resistant to current therapies.
How similar studies have gone: Previous research has shown promise in targeting DNA damage response pathways in cancer therapy, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Hong, Jiyong — Duke University
- Study coordinator: Hong, Jiyong
Related research
Other NIH-funded projects on the same topics.
-
Investigating genetic factors in Lewy body diseases
This study is looking at how changes in a specific gene might play a role in conditions like Parkinson's disease and dementia, so that people can better understand how their genetics affect their health and possibly find more tailored treatments.
-
Targeting the PAX3-FOXO1 protein in a deadly childhood cancer
This study is looking at a specific protein that helps a tough childhood cancer called alveolar rhabdomyosarcoma, with the goal of finding new ways to treat kids who have this illness.
-
Improving population health by studying reproduction and development
This study is looking at how different things in our environment can impact pregnancy and the health of babies, and it’s for people who are planning to have children or are already parents, as it aims to help improve understanding and outcomes for everyone involved.
-
Modeling axon degeneration in C. elegans to help ALS patients
Researchers are using a tiny worm model to uncover how axons break down, which could point to new ways to help people with ALS and related nerve diseases.
-
Induced Suppression of Platelet Activity in Aneurysmal SAH Management
A new approach tests whether carefully reducing platelet activity can improve outcomes after aneurysmal subarachnoid hemorrhage.
-
AI-enhanced virtual reality tool to support remote emergency brain surgery training in Tanzania
A new AI-powered virtual reality tool helps non-experts in low-resource areas get real-time remote guidance for emergency traumatic brain injury surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.